Trial Profile
A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs EQ 101 (Primary)
- Indications Cutaneous T-cell lymphoma; Large granular lymphocytic leukaemia; Mycosis fungoides; Sezary syndrome
- Focus Adverse reactions
- Sponsors Bioniz
- 04 Jan 2021 Status changed from recruiting to completed, according to a Bioniz media release,
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 05 Dec 2020 Positive results presented in the Bioniz Media Release.